

850-060-0226**Formulary Compendium Classifications**

The Formulary Council has approved the following pharmacologic-therapeutic classifications in addition to drugs previously approved by the Formulary Council and listed in 850-060-0225. This listing does not supersede the education and training requirement established in 850-060-0212 for administration of IV agents. The Formulary Council may consider new agents, substances and pharmacologic-therapeutic classifications for addition to this list.

(1) Antihistamine Drugs;

- (a) First Generation Antihistamine Drugs;
 - (A) Ethanolamine Derivatives;
 - (B) Ethylenediamine Derivatives;
 - (C) Phenothiazine Derivatives;
 - (D) Piperazine Derivatives;
 - (E) Propylamine Derivatives;
 - (F) Miscellaneous Derivatives;
- (b) Second Generation Antihistamines.

(2) Anti-Infective Agents;

- (a) Anthelmintics;
- (b) Antibacterials;
 - (A) Aminoglycosides;
 - (B) Cephalosporins;
 - (i) First Generation Cephalosporins;
 - (ii) Second Generation Cephalosporins;
 - (iii) Third Generation Cephalosporins;
 - (iv) Fourth Generation Cephalosporins.
 - (C) Miscellaneous β -Lactams;
 - (i) Carbacephems;
 - (ii) Carbapenems;
 - (iii) Cephamycins;
 - (iv) Monobactams.
 - (D) Chloramphenicol;
 - (E) Macrolides.
 - (i) Erythromycins;
 - (ii) Ketolides;
 - (iii) Other Macrolides.
 - (F) Penicillins;
 - (i) Natural Penicillins;
 - (ii) Aminopenicillins;
 - (iii) Penicillinase-resistant Penicillins;
 - (iv) Extended-spectrum Penicillins.
 - (G) Quinolones;
 - (H) Sulfonamides;
 - (I) Tetracyclines: Glycylcyclines;
 - (J) Antibacterials, Miscellaneous.
 - (i) Aminocyclitols;
 - (ii) Bacitracins;
 - (iii) Cyclic Lipopeptides;

- (iv) Glycopeptides;
- (v) Lincomycins;
- (vi) Oxazolidinones;
- (vii) Polymyxins;
- (viii) Rifamycins;
- (ix) Streptogramins;
- (c) Antifungals;
 - (A) Allylamines;
 - (B) Azoles;
 - (C) Echinocandins;
 - (D) Polyenes;
 - (E) Pyrimidines;
 - (F) Antifungals, Miscellaneous.
- (d) Antimycobacterials;
 - (A) Antituberculosis Agents;
 - (B) Antimycobacterials, Miscellaneous.
- (e) Antivirals;
 - (A) Adamantanes;
 - (B) Antiretrovirals;
 - (i) HIV Fusion Inhibitors;
 - (ii) HIV Protease Inhibitors;
 - (iii) Integrase Inhibitors;
 - (iv) Nonnucleoside Reverse Transcriptase Inhibitors;
 - (v) Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
 - (C) Interferons;
 - (D) Monoclonal Antibodies;
 - (E) Neuraminidase Inhibitors;
 - (F) Nucleosides and Nucleotides;
 - (G) Antivirals, Miscellaneous;
- (f) Antiprotozoals;
 - (A) Amebicides;
 - (B) Antimalarials;
 - (C) Antiprotozoals, Miscellaneous.

(3) Antineoplastic Agents (oral and topical only) limited to the following:

- (a) 5FU;
- (b) Anastrozole;
- (c) Letrozole;

- (d) Mechlorethamine;
- (e) Megestrol;
- (f) Mercaptopurine;
- (g) Methotrexate;
- (h) Tamoxifen;
- (i) Tretinoin.

(4) Autonomic Drugs;

- (a) Parasympathomimetic (Cholinergic) Agents;
- (b) Anticholinergic Agents: Antimuscarinics/
Antispasmodics;
- (c) Sympathomimetic (Adrenergic) Agents;
 - (A) α -Adrenergic Agonists;
 - (B) β - Adrenergic Agonists;
 - (i) Non-selective β - Adrenergic Agonists;
 - (ii) Selective β_1 - Adrenergic Agonists;
 - (iii) Selective β_2 - Adrenergic Agonists;
 - (C) α -And β -Adrenergic Agonists;
- (d) Sympatholytic (Adrenergic Blocking)
Agents;
- (e) Skeletal Muscle Relaxants;
 - (A) Centrally Acting Skeletal Muscle
Relaxants;
 - (B) Direct-acting Skeletal Muscle Relaxants;
 - (C) GABA-derivative Skeletal Muscle
Relaxants;
 - (D) Neuromuscular Blocking Agents;
 - (E) Skeletal Muscle Relaxants,
Miscellaneous.
- (f) Autonomic Drugs, Miscellaneous.

(5) Blood Derivatives.

**(6) Blood Formation, Coagulation, and
Thrombosis;**

- (a) Antianemia Drugs: Iron Preparations;
- (b) Antithrombotic Agents;
 - (A) Anticoagulants;
 - (i) Coumarin Derivatives;
 - (ii) Direct Thrombin Inhibitors;
 - (iii) Heparins;
 - (iv) Anticoagulants, Miscellaneous.
 - (B) Platelet-reducing Agents;
 - (C) Platelet-aggregation Inhibitors;
 - (D) Thrombolytic Agents;
- (c) Hematopoietic Agents;
- (d) Hemorrhologic Agents;
- (e) Antihemorrhagic Agents;
 - (A) Antiheparin Agents;
 - (B) Hemostatics.

(7) Cardiovascular Drugs;

- (a) Cardiac Drugs;
 - (A) Antiarrhythmic Agents;
 - (i) Class Ia Antiarrhythmics;
 - (ii) Class Ib Antiarrhythmics;
 - (iii) Class Ic Antiarrhythmics;
 - (iv) Class III Antiarrhythmics;
 - (v) Class IV Antiarrhythmics.
 - (B) Cardiotonic Agents;
 - (C) Cardiac Drugs, Miscellaneous.
 - (b) Antilipemic Agents;
 - (A) Bile Acid Sequestrants;
 - (B) Cholesterol Absorption Inhibitors;
 - (C) Fibric Acid Derivatives;
 - (D) HMG-CoA Reductase Inhibitors;
 - (E) Antilipemic Agents, Miscellaneous.
 - (c) Hypotensive Agents;
 - (A) Calcium-Channel Blocking Agents;
 - (B) Central α -Agonists;
 - (C) Direct Vasodilators;
 - (D) Peripheral Adrenergic Inhibitors.
 - (d) Vasodilating Agents;
 - (A) Nitrates and Nitrites;
 - (B) Phosphodiesterase Inhibitors;
 - (C) Vasodilating Agents, Miscellaneous.
 - (e) Sclerosing Agents;
 - (f) α -Adrenergic Blocking Agents;
 - (g) β -Adrenergic Blocking Agents;
 - (h) Calcium-Channel Blocking Agents;
 - (A) Dihydropyridines;
 - (B) Calcium-Channel Blocking Agents,
Miscellaneous;
 - (i) Renin-Angiotensin-Aldosterone System
Inhibitors;
 - (A) Angiotensin-Converting Enzyme
Inhibitors;
 - (B) Angiotensin II Receptor Antagonists;
 - (C) Mineralocorticoid (Aldosterone)
Receptor Antagonists;
 - (D) Renin Inhibitors.
- (8) Central Nervous System Agents;**
- (a) Analgesics and Antipyretics;
 - (A) Nonsteroidal Anti-inflammatory Agents;
 - (i) Cyclooxygenase-2 (COX-2)
Inhibitors;
 - (ii) Salicylates;
 - (iii) Other Nonsteroidal Anti-
inflammatory Agents;

- (B) Opiate Agonists;
- (C) Opiate Partial Agonists;
- (D) Analgesics and Antipyretics,

Miscellaneous.

- (b) Opiate Antagonists;
- (c) Anticonvulsants;
 - (A) Benzodiazepines;
 - (B) Hydantoins;
 - (C) Succinimides;
 - (D) Anticonvulsants, Miscellaneous.
- (d) Psychotherapeutic Agents;
 - (A) Antidepressants;
 - (i) Monoamine Oxidase Inhibitors;
 - (ii) Selective Serotonin- and Norepinephrine-reuptake Inhibitors;
 - (iii) Selective Serotonin- Reuptake Inhibitors;
 - (iv) Serotonin Modulators;
 - (v) Tricyclics and Other Norepinephrine-reuptake Inhibitors.
 - (vi) Antidepressants, Miscellaneous.
 - (B) Antipsychotics.
- (e) Anorexigenic Agents and Respiratory and Cerebral Stimulants.
 - (A) Amphetamines.
 - (B) Anorexigenic Agents and Respiratory and Cerebral Stimulants, Miscellaneous.
- (f) Anxiolytics, Sedatives, and Hypnotics, does not include Barbiturates;
 - (A) Benzodiazepines;
 - (B)(i) Anxiolytics, Sedatives, and Hypnotics; Miscellaneous;
 - (ii) Nitrous oxide;
- (g) Antimanic Agents;
- (h) Antimigraine Agents: Selective Serotonin Agonists;
 - (i) Antiparkinsonian Agents;
 - (A) Adamantanes;
 - (B) Anticholinergic Agents;
 - (C) Catechol-O-Methyltransferase (COMT) Inhibitors;
 - (D) Dopamine Precursors;
 - (E) Dopamine Receptor Agonists;
 - (i) Ergot-derivative Dopamine Receptor Agonists;
 - (ii) Non-ergot-derivative Dopamine Receptor Agonists;
 - (F) Monoamine Oxidase B Inhibitors;
 - (j) Central Nervous System Agents, Miscellaneous.

(9) Contraceptives (foams, devices).

(10) Diagnostic Agents.

(11) Disinfectants (for Agents used on objects other than skin).

(12) Electrolytic, Caloric, and Water Balance;

- (a) Acidifying Agents;
- (b) Alkalinizing Agents;
- (c) Ammonia Detoxicants;
- (d) Replacements Preparations;
- (e) Ion-Removing Agents;
 - (A) Calcium-removing Agents;
 - (B) Potassium-removing Agents;
 - (C) Phosphate-removing Agents;
 - (D) Other Ion-removing Agents;
- (f) Caloric Agents;
- (g) Diuretics;
 - (A) Loop Diuretics;
 - (B) Osmotic Diuretics;
 - (C) Potassium-sparing Diuretics;
 - (D) Thiazide Diuretics;
 - (E) Thiazide-like Diuretics;
 - (F) Diuretics, Miscellaneous;
- (h) Irrigation Solutions;
- (i) Uricosuric Agents.

(13) Enzymes.

(14) Respiratory Tract Agents;

- (a) Antihistamines;
- (b) Antitussives;
- (c) Anti-inflammatory Agents;
 - (A) Leukotriene Modifiers;
 - (B) Mast-cell Stabilizers;
- (d) Expectorants;
- (e) Pulmonary Surfactants;
- (f) Respiratory Agents, Miscellaneous.

(15) Eye, Ear, Nose, and Throat (EENT) Preparations;

- (a) Antiallergic Agents;
- (b) Anti-infectives;
 - (A) Antibacterials;
 - (B) Antifungals;
 - (C) Antivirals;
 - (D) Anti-infectives, Miscellaneous.
- (c) Anti-inflammatory Agents;

- (A) Corticosteroids;
- (B) Nonsteroidal Anti-inflammatory Agents;
- (C) Anti-inflammatory Agents,

Miscellaneous.

- (d) Local Anesthetics;
- (e) Mydriatics;
- (f) Mouthwashes and Gargles;
- (g) Vasoconstrictors;
- (h) Antiglaucoma Agents;
 - (A) α -Adrenergic Agonists;
 - (B) β -Adrenergic Agents;
 - (C) Carbonic Anhydrase Inhibitors;
 - (D) Miotics;
 - (E) Prostaglandin Analogs;
- (i) EENT Drugs, Miscellaneous.

(16) Gastrointestinal Drugs;

- (a) Antacids and Adsorbents;
- (b) Antidiarrhea Agents;
- (c) Antiflatulents;
- (d) Cathartics and Laxatives;
- (e) Cholelitholytic Agents;
- (f) Emetics;
- (g) Antiemetics;
 - (A) Antihistamines;
 - (B) 5-HT₃ Receptor Antagonists;
 - (C) Antiemetics, Miscellaneous.
- (h) Antiulcer Agents and Acid Suppressants;
 - (A) Histamine H₂-Antagonists;
 - (B) Prostaglandins;
 - (C) Protectants;
 - (D) Proton-pump Inhibitors;
- (i) Prokinetic Agents;
- (j) Anti-inflammatory Agents;
- (k) GI Drugs, Miscellaneous.

(17) Gold Compounds.

(18) Heavy Metal Antagonists.

NOTE: IV administration requires education and training compliance with 850-060-0212.

(19) Hormones and Synthetic Substitutes;

- (a) Adrenals;
- (b) Androgens;
- (c) Contraceptives;
- (d) Estrogens and Antiestrogens;
 - (A) Estrogens;
 - (B) Estrogen Agonists-Antiagonists.
- (e) Gonadotropins;

- (f) Antidiabetic Agents;
 - (A) α -Glucosidase Inhibitors;
 - (B) Amylinomimetics;
 - (C) Biguanides;
 - (D) Dipeptidyl Peptidase (DDP-4)

Inhibitors;

- (E) Incretin Mimetics;
- (F) Insulins;
- (G) Meglitinides;
- (H) Sulfonylureas;
- (I) Thiazolidinediones;
- (J) Miscellaneous.

(g) Antihypoglycemic Agents: Glycogenolytic Agents;

- (h) Parathyroid;
- (i) Pituitary;
- (j) Somatotropin Agonists and Antagonists;
 - (A) Somatotropin Agonists;
 - (B) Somatotropin Antagonists;
- (k) Progestins;
- (l) Thyroid and Antithyroid Agents;
 - (A) Thyroid Agents;
 - (B) Antithyroid Agents.

(20) Local Anesthetics.

(21) Oxytocics, except for Mifepristone.

(22) Serums, Toxoids, and Vaccines;

- (a) Serums;
- (b) Toxoids;
- (c) Vaccines.

(23) Skin and Mucous Membrane Agents;

- (a) Anti-infectives;
 - (A) Antibacterials;
 - (B) Antivirals;
 - (C) Antifungals;
 - (i) Alkylamines;
 - (ii) Azoles;
 - (iii) Benzylamines;
 - (iv) Hydroxypyridones;
 - (v) Polyenes;
 - (vi) Thiocarbamates;
 - (vii) Antifungals, Miscellaneous.
 - (D) Scabicides and Pediculicides;
 - (E) Local Anti-infectives, Miscellaneous.
- (b) Anti-inflammatory Agents;
- (c) Antipruritics and Local Anesthetics;
- (d) Astringents;

- (e) Cell Stimulants and Proliferants;
 - (f) Detergents;
 - (g) Emollients, Demulcents, and Protectants;
 - (h) Keratolytic Agents;
 - (i) Keratoplastic Agents;
 - (j) Depigmenting and Pigmenting Agents;
 - (A) Depigmenting Agents;
 - (B) Pigmenting Agents;
 - (k) Sunscreen Agents;
 - (l) Skin and Mucous Membrane Agents,
- Miscellaneous.

(24) Smooth Muscle Relaxants;

- (a) Gastrointestinal Smooth Muscle Relaxants;
- (b) Genitourinary Smooth Muscle Relaxants;
- (c) Respiratory Smooth Muscle Relaxants.

(25) Vitamins and Minerals.

(26) Miscellaneous Therapeutic Agents;

- (a) Alcohol Deterrents limited to the following:
 - (A) Acamprosate;
 - (B) Disulfiram;

- (C) Naltrexone.
 - (b) 5-a Reductase Inhibitors;
 - (c) Antidotes;
 - (d) Antigout Agents;
 - (e) Biologic Response Modifiers
 - (A) Interferons;
 - (B) Dimethyl Fumarate;
 - (f) Bone Resorption Inhibitors;
 - (g) Cariostatic Agents;
 - (h) Complement Inhibitors;
 - (i) Disease-Modifying Antirheumatic Agents;
 - (j) Gonadotropin-releasing Hormone
- Antagonists;
- (k) Immunosuppressive Agents;
 - (l) Other Miscellaneous Therapeutic Agents
- limited to the following:
- (A) Alfuzosin Hydrochloride;
 - (B) Drotrecogin Alfa (Activated);
 - (C) Lanreotide Acetate;
 - (D) Rilonecept;
 - (E) Sapropterin Dihydrochloride;
 - (F) Tamsulosin Hydrochloride.

Stat. Auth.: ORS 685.125

Stats. Implemented: ORS 685.145

Hist.: BNE 1-2002, f. & cert. ef. 2-19-02; BNE 4-2002, f. & cert. ef. 8-8-02; BNE 3-2003, f. & cert. ef. 6-9-03; BNE 5-2003, f. & cert. ef. 12-5-03; BNE 5-2004, f. & cert. ef. 6-10-04; Renumbered from 850-010-0226, BNE 8-2005, f. & cert. ef. 10-27-05; BNE 9-2005, f. & cert. ef. 12-12-05; BNE 4-2006, f. & cert. ef. 12-11-06; BNE 3-2007, f. & cert. ef. 6-12-07; BNE 1-2008, f. & cert. ef. 2-19-08; BNE 2-2008, f. & cert. ef. 3-21-08; BNE 6-2008, f. & cert. ef. 6-11-08; BNE 7-2008, f. & cert. ef. 12-8-08; BNE 2-2009, f. & cert. ef. 6-17-09; BNE 7-2009, f. 12-14-09, cert. ef. 1-1-10; OBNM 5-2010, f. & cert. ef. 6-30-10; OBNM 7-2010, f. & cert. ef. 12-13-10; OBNM 2-2011, f. & cert. ef. 4-12-11; OBNM 4-2011, f. & cert. ef. 6-15-11; OBNM 3-2012, f. & cert. ef. 6-15-12; OBNM 1-2014, f. & cert. ef. 4-9-14; OBNM 3-2014, f. & cert. ef. 7-10-14; OBNM 5-2015, f. & cert. ef. 8-28-15